Japanese researchers have been able to improve the symptoms of Parkinson's disease in monkeys by transplanting nerve cells derived from embryonic stem cells into their brains, the team has announced. The finding is the world's first reported success of its kind with a primate, according to the research team led by associate professor Jun Takahashi of Kyoto University's Institute for Frontier Medical Sciences
NEW YORK (Reuters Health) – To test whether a new drug is an improvement over existing treatments, the ideal clinical trial would compare the medications head to head, but few trials of rheumatoid arthritis treatments happen that way, according to a new study. Instead, researchers found that for certain new rheumatoid arthritis medications, subjects in the comparison groups were often assigned to continue taking a drug that didn't help them or to take a fake drug called a placebo — in both cases effectively depriving those patients of treatment for their disease. “Of course it's easier to compare to a placebo than an active treatment but in no way can it justify exposing patients to irreversible morbidity,” said Dr
By David Voreacos – Thu Feb 16 18:24:47 GMT 2012 Johnson & Johnson’s anti-psychotic drug Risperdal wasn’t a substantial factor in causing a Nebraska man’s diabetes, even though J&J failed to adequately warn his doctor about the drug’s risks, a New Jersey jury ruled.
By Dr Ananya Mandal, MD Researchers from United States have successfully healed the scars caused by a heart attack using stem cells gathered from the patient's own heart. The amount of scar tissue was halved in the small safety trial reported in the Lancet medical journal.
CLEVELAND, Feb. 14, 2012 /PRNewswire/ – Milo Biotechnology will receive $250,000 from JumpStart Inc., a nonprofit investing intensive business assistance and some capital into early stage Northeast Ohio-based tech companies. A clinical stage startup developing a therapy to increase muscle strength and improve the quality of life of muscular dystrophy patients, Milo is the 61st company in JumpStart's portfolio. ”There are limited treatment options for muscular dystrophy and approved therapies are inadequate or can cause significant side effects,” says JumpStart's Mike Lang
February 15, 2012, 12:06 AM EST By Ryan Flinn (Adds comment from researcher in 13th paragraph.) Feb. 14 (Bloomberg) — Stem cells grown from patients’ own cardiac tissue can heal damage once thought to be permanent after a heart attack, according to a study that suggests the experimental approach may one day help stave off heart failure.
13 February 2012 Last updated at 19:52 ET By James Gallagher Health and science reporter, BBC News Damage caused by a heart attack has been healed using stem cells gathered from the patient's own heart, according to doctors in the US. The amount of scar tissue was halved in the small safety trial reported in the Lancet medical journal.
MARLBOROUGH, Mass.–(BUSINESS WIRE)– Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today the dosing of third patient in its Phase 1/2 trial for Stargardt’s macular dystrophy (SMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs). The patient was treated on Monday (Feb.
Home > News > health-news Washington, Feb 13 : Children with juvenile idiopathic arthritis (JIA) are four times likelier to have cancer than those without the disease, researchers have revealed. The findings suggest JIA treatment, such as tumor necrosis factor (TNF) inhibitors, does not necessarily explain the development of cancer in this pediatric population
Public release date: 13-Feb-2012 [ | E-mail | Share ] Contact: Dawn Peters healthnews@wiley.com 781-388-8408 Wiley-Blackwell New research reports that incident malignancy among children with juvenile idiopathic arthritis (JIA) is four times higher than in those without the disease. Findings now available in Arthritis & Rheumatism, a journal published by Wiley-Blackwell on behalf of the American College of Rheumatology (ACR), suggest JIA treatment, such as tumor necrosis factor (TNF) inhibitors, does not necessarily explain the development of cancer in this pediatric population.
Children with juvenile idiopathic arthritis (JIA), the most common form of childhood arthritis, may be at higher risk of developing cancer than children who do not have the condition, according to a new study published in the journal Arthritis & Rheumatism. Researchers identified 7,812 children with JIA and compared them with thousands of children not affected by JIA and found that the arthritic children developed about four times as many new growths considered likely to be cancerous as children who did not have arthritis. They followed the children for about 18 months
February 14, 2012, 12:22 AM EST By Ryan Flinn Feb. 14 (Bloomberg) — Stem cells grown from patients’ own cardiac tissue can heal damage once thought to be permanent after a heart attack, according to a study that suggests the experimental approach may one day help stave off heart failure. In a trial of 25 heart-attack patients, 17 who got the stem cell treatment showed a 50 percent reduction in cardiac scar tissue compared with no improvement for the eight who received standard care.
MENLO PARK, Calif., Feb. 9, 2012 /PRNewswire/ – Auxogyn, Inc., a privately-held company advancing women's reproductive health, announced today that the Personalized Medicine World Conference (PMWC) and Prescience International selected the Auxogyn as the 'Most Promising Company' at PMWC2012 annual conference, held January 23-24, 2012.
WASHINGTON–(BUSINESS WIRE)– Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood issued the following statement regarding the newly released U.S. Food and Drug Administration (FDA) guidance for the review and approval of biosimilars: “Today the FDA announced specific guidance for the review and approval of biosimilars, medicines that are similar to, but not exact replicas of, innovator biologics
20-10-2011 12:44 Eric Nelson, Center for Veterinary Medicine This presentation discusses FDA’s recent strategic review, known as the Animal Feed Safety System Initiative. It provides information on FDA’s early efforts to ensure feed safety for animals and people, with animal feed regulations designed to ensure safe drug use in feed, resulting in Good Manufacturing Practice (GMP) regulations
The phase I trial follows promising studies on mice showing that such transplants were able to rebuild the structures of the inner ear, and some anecdotal evidence from humans, sparking hope of a cure for some forms of deafness. One of those people is two-year-old Finn McGrath, who suffered brain damage after being deprived of oxygen during a prolonged and complicated delivery, according to his mother, Laura.
WASHINGTON, D.C. — Researchers at the U.S. Department of Energy’s (DOE’s) Joint BioEnergy Institute (JBEI) recently announced a major breakthrough in engineering systems of RNA molecules through computer-assisted design